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Mouse allergy in both laboratory workers and in inner-city children is associated with aller-
gic rhinitis and asthma, posing a serious public health concern. Urine is a major source of 
mouse allergens, as mice spray urine onto their surroundings, where the proteins dry up 
and become airborne on dust particles. Here, we tested whether oligopeptides that are 
abundant in mouse urine may contribute to mouse allergic T cell response. Over 1,300 
distinct oligopeptides were detected by mass spectrometry analysis of the low molecular 
weight filtrate fraction of mouse urine (LoMo). Posttranslationally modified peptides were 
common, accounting for almost half of total peptides. A pool consisting of 225 unique 
oligopeptides of 13 residues or more in size identified within was tested for its capacity 
to elicit T cell reactivity in mouse allergic donors. Following 14-day in vitro stimulation of 
PBMCs, we detected responses in about 95% of donors tested, directed against 116 
distinct peptides, predominantly associated with Th2 cytokines (IL-5). Peptides from 
non-urine related proteins such as epidermal growth factor, collagen, and Beta-globin 
accounted for the highest response (15.9, 9.1, and 8.1% of the total response, respec-
tively). Peptides derived from major urinary proteins (MUPs), kidney androgen-regulated 
protein (KAP), and uromodulin were the main T cell targets from kidney or urine related 
sources. Further ex vivo analysis of enrichment of 4-1BB expressing cells demonstrated 
that LoMo pool-specific T cell reactivity can be detected directly ex vivo in mouse allergic 
but not in non-allergic donors. Further cytometric analysis of responding cells revealed 
a bone fide memory T  cell phenotype and confirmed their Th2 polarization. Overall, 
these data suggest that mouse urine-derived oligopeptides are a novel target for mouse 
allergy-associated T cell responses, which may contribute to immunopathological mech-
anisms in mouse allergy.
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inTrODUcTiOn
The kidneys filter unwanted substances from the blood and produce urine to excrete them. There 
are three main steps of urine formation: glomerular filtration, reabsorption, and secretion. These 
processes ensure that only waste and excess water are removed from the body. Nearly all proteins 
and oligopeptides are reabsorbed, preventing them from disappearing from the body through the 
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urine. The molecular weight cutoff for glomerular filtration is 
thought to be 30–50 kDa (1).
In humans, the excretion of more than 0.5 mg of protein daily 
(proteinuria) is considered abnormal and of potential pathologi-
cal significance. For example, determination of peptide excretion 
rates by filtration through a 10  kDa molecular-weight-cutoff 
membrane showed that albumin and other protein-derived pep-
tides are excreted at high concentrations (up to 4 g/day) in the 
urine of patients with diabetes (2).
The urine protein content of mice, in contrast to most other 
mammals, is high (3), and proteinuria as a normal condition 
was recognized as early as 1933 (4–6). The high protein content 
of mouse urine has consequences in terms of the induction 
of allergic reactions in humans exposed to mice. Mice spray 
urine onto their surroundings, and as the proteins dry up, they 
become airborne on dust particles (7). Mouse urine contains 
specific proteins, termed major urinary proteins (MUP), which 
are involved in mouse-to-mouse communication and territorial 
marking (7–9). MUP, because of their structure, relatively small 
size, and biological function as olfactory proteins, are volatile. 
It is thought that their inhalation is a contributor to their high 
allergenic potential (10, 11).
Mouse urine is indeed the most prominent source of murine 
allergens, which have been described over two decades ago (12, 13). 
In addition to Mus m1, several new mouse proteins have recently 
been shown to be human T cell targets in mouse allergy (14–16). 
High concentrations of airborne rodent allergens in laborato-
ries and inner-city apartments (17–19) have been associated 
with allergic rhinitis, allergic conjunctivitis, and high incidence 
of asthma (20–23), and thus constitute a serious public health 
concern.
Because allergens in general are defined on the basis of IgE 
reactivity, it is not surprising that all mouse allergens are proteins 
with a molecular weight of 10  kDa or higher (24). However, 
mouse urine is also an abundant source of relatively small 
molecular weight peptides, either derived from the breakdown 
of proteins or actual excretion. The mouse urine peptidome has 
been characterized by mass spectroscopy (9, 25).
Alongside the well-studied IgE-mediated allergic reaction 
(24), T cell reactivity and recognition of allergen T cell epitopes 
also plays an important role in the sensitization and potentia-
tion of allergic reactions (16, 26–29). Small peptides in the urine 
are potentially volatile and could be adsorbed through the nose 
and mucosal surfaces. While their small size would make them 
unlikely to contribute to IgE responses, peptides naturally bound 
to HLA class II molecules and recognized by human helper 
T cells are about 15 residues in size. Thus, recognition of peptides 
derived from mouse urine by specific T cells could represent a 
novel contributor to overall adaptive immune responses associ-
ated with inhalant allergens.
MaTerials anD MeThODs
study Population and PBMc isolation
A cohort of 29 mouse-sensitized patients, as defined by mouse-
specific IgE titers of >0.35  kUA/l, was studied. A cohort of 10 
non-allergic and non-exposed subjects, defined by the lack of 
mouse-specific IgE titers (<0.35 kUA/l) and no known exposure 
to mouse allergens was used as a negative control. Individual 
subjects were recruited from San Diego, CA, USA, and New York 
City, NY, USA following Institutional Review Board approval 
(IRB protocols: VD-112-0217, GCO 13-0691). All subjects 
enrolled in this study provided written consent. Demographic 
and clinical information is summarized in Tables S1A–C in 
Supplementary Material. IgE titers were determined from plasma 
by ImmunoCAP (ThermoFisher, Uppsala, Sweden). PBMCs 
were isolated from whole blood by density gradient centrifuga-
tion according to manufacturers’ instructions (Ficoll-Hypaque, 
Amersham Biosciences, Uppsala, Sweden).
Urine and epithelia Mouse allergen 
extracts
Mouse epithelial extract (EPTH) was purchased from Greer 
(Lenoir, NC). Mouse urine (mixed gender pooled, unfiltered) was 
purchased from CliniScinces (Nanterre, France). Low molecular 
flow-through components (<3  kDa) were isolated by filtration 
centrifugation using Amicon Ultracel tubes (Merck Millipore, 
Darmstadt, Germany) of mouse urine and further analyzed by 2D 
LCMS to identify specific peptide sequences, after de-salting gel 
chromatography. The high molecular weight fraction (>3 kDa) 
was washed six times with PBS, each time followed by repeated 
centrifugation in Amicon Ultracel tubes with a cutoff of 3 kDa. 
Protein/peptide content was determined by Pierce BCA Protein 
Assay Kit (ThermoFisher). The resulting urine high molecular 
weight (PUR) and low molecular weight (FLT) extracts were 
lyophilized and subsequently resuspended in PBS.
Mass spectrometry analysis
Lyophilized mouse urine flow-through was resuspended in 
10% acetic acid and loaded onto a reverse-phase column (pore 
size, 90  Å; 2  mm i.d. by 150  mm long; Jupiter 4  µm Proteo; 
Phenomonex) with a Michrom Paradigm MG4 high-pressure 
liquid chromatograph (HPLC) and eluted at pH 10 with an 
organic gradient of 2–10% acetonitrile for 2 min followed by 
10–60% acetonitrile for 60 min in water with 40 mM ammonium 
bicarbonate. Fractions were collected every minute resulting in 
49 peptide-containing fractions. Each of these fractions was 
dried and resuspended in 10% acetic acid and placed into an 
Eksigent NanoLC 400 U-HPLC auto sampler system (Sciex). 
Approximately 20% of each fraction was injected onto a nano-
LC trap column (C18 trap column, 350 µm i.d. by 0.5 mm long 
with 3-µm particles and 120-Å pores, ChromXP) and washed 
for 5  min in solvent A (98% water, 2% actetonitrile, 0.1% 
formic acid).
The peptides eluted from the trap column were put in line with 
a separation column (C18 trap column, 75 µm i.d. by 15 cm long 
with 3-µm particles and 120-Å pores, ChromXP). The mobile 
phase solvents were solvent A (98% water, 2% actetonitrile, 
0.1% formic acid) and solvent B (5% water, 95% actetonitrile, 
0.1% formic acid). The elution consisted of two linear gradients 
of solvent A and B: 10–40% solvent A for 70 min then 40–80% 
solvent B for 10  min. Eluting peptides were ionized with a 
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nanospray III ion source and analyzed with a 5600 Triple-TOF 
mass spectrometer (Sciex). Survey and fragment spectra of elut-
ing ions were collected with data-dependent acquisition (DDA) 
in positive ion polarity.
Peptide sequences were derived from the DDA spectra using 
PEAKS 7.0 software (Bioinformatic Solutions). Fragment spec-
tra were searched against the Uniprot murine (Mus musculus) 
proteome with a precursor mass error tolerance of 50 ppm and 
a fragment mass error of 0.05  Da. Variable posttranslational 
modifications consisted of: cysteinylation (C), hydroxylation 
(D, K, N, P, R, Y), dihydroxy (F, K, P, R), oxidation (M, W, H), 
acetylation (N-term, R), deamidation (N, Q), pyroglutamate 
from glutamic acid, and sodium adducts (D, E, c-term). A false 
discovery rate (FDR) was estimated for assigned sequences 
using a target-decoy fusion approach provided by PEAKS 7.0. 
All sequences were assigned at a 1% FDR.
Peptide synthesis and loMo Megapool 
generation
225 oligopeptides identified within the low molecular weight 
filtrate fraction of mouse urine were synthesized by A and A 
(San Diego, CA, USA) as crude material on a small (1-mg) scale. 
Individual peptides were resuspended in DMSO at a final con-
centration of 40 mg/ml. The peptides were pooled, lyophilized, 
and the resulting megapool (LoMo) was resuspended to a final 
concentration of 1 mg/ml.
hla Typing and inferred restriction
Donors were HLA typed either at the La Jolla Institute or by an 
ASHI-accredited laboratory at Murdoch University (Western 
Australia). HLA typing was performed for Class I (HLA A; B; C) 
and Class II (DQA1; DQB1, DRB1 3,4,5; DPB1) using locus-
specific PCR amplification on genomic DNA. Primers used 
for amplification employed patient-specific barcoded pri mers. 
Amplified products were quantitated and pooled by subject and 
up to 48 subjects were pooled. An unindexed (454 8-lane runs) or 
indexed (8 indexed MiSeq runs) library was then quantitated using 
Kappa universal QPCR library quantification kits. Sequencing 
was performed using either a Roche 454 FLX+ sequencer with 
titanium chemistry or an Illumina MiSeq using a 2 × 300 paired-
end chemistry. Reads were quality-filtered and passed through a 
proprietary allele calling algorithm and analysis pipeline using 
the latest IMGT HLA allele database as a reference. Potential 
HLA-epitope restriction odds ratios and relative frequencies were 
calculated using the RATE program (30).
stimulation and expansion of T cells  
With loMo Megapool
For in  vitro expansion of LoMo-specific T  cells, PBMCs of 
mouse-sensitized individuals were stimulated with LoMo 
megapool at a final concentration of 1 µg/ml. Stimulation con-
centrations to induce optimal T cell responses were previously 
determined by titration (data not shown). Cells were cultured 
in RPMI 1640 supplemented with 5% human AB serum in 24 
well plates (BD Bioscience, San Diego, CA, USA) at a density of 
2 × 106/ml and incubated at 37°C. IL-2 was added every 3 days 
after initial stimulation. Cells were harvested on day 14 and 
screened for IFNγ and IL-5-production by ELISPOT.
Dual elisPOT assays
The production of IFNγ and IL-5 from cultured PBMCs 
in response to antigenic stimulation was assessed by dual 
ELISPOT assays as described previously (28). Cells (1  ×  105 
cells/well) were stimulated with either peptide pools (1 µg/ml), 
individual peptides (10 µg/ml), or PHA (10 µg/ml), or medium 
containing DMSO corresponding to the DMSO % in the pools/
peptides as a control. Spot-forming cells (SFC) were counted by 
computer assisted image analysis (KS-ELISPOT reader, Zeiss, 
Munich, Germany). Criteria for positivity were ≥20 SFCs per 
106 PBMCs, p < 0.05 by Student’s t-test or by a Poisson distribu-
tion test, and a stimulation index ≥2. Positive pools (≥100 SFC) 
were deconvoluted to identify the individual epitopes inducing 
the response.
ige reactivity against PUr extract, loMo 
Peptides, and epidermal growth Factor 
(egF) restriction of Dominant epitopes
LoMo peptides (10 μg/ml), high molecular weight (PUR) extract 
(10 μg/ml), and mouse rEGF (ThermoFisher) (2.5 μg/ml) were 
incubated overnight at 4°C and then blocked with 1% BSA in 
PBS for 2 h at room temperature. Plasma was allowed to react for 
2 h at room temperature with mild agitation. IgE was detected 
by incubation with HRP-conjugated antihuman IgE mono-
clonal antibody for 1  h at room temperature (ThermoFisher). 
The plates were developed by addition of the TMB substrate. 
The absorbance at 450  nm was measured with a VersaMax 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). A 
standard curve was run in parallel with purified antihuman IgE 
as a capture antibody and titration of a recombinant human IgE.
activation-induced Marker (aiM), ics,  
and 4-1BB enrichment assays
The AIM assay was previously described (31). This assay 
detects cells that are activated as a result of antigen-specific 
stimulation by upregulation of activation-induced surface 
markers. Here, we employ 4-1BB (CD137) enrichment (CD137 
MicroBead Kit, Miltenyi, Germany) followed by staining with a 
cocktail containing CD4-APC-ef780, CD3-AF700, CD8/CD14/
CD19-V500, CD45RA-eF450, CCR7-PerCPCy5.5, 4-1BB-APC, 
and OX40-PECy7 (see Table S2 in Supplementary Material). 
Cryopreserved PBMCs were thawed, and 1 ×  106 cells/condi-
tion were stimulated with LoMo megapool (2  µg/ml) or high 
molecular weight (PUR) urine extracts (10 µg/ml) in 5% human 
serum (Gemini Bioproducts) for 24  h. DMSO (0.25%) with 
medium was used as negative control. For intracellular cytokine 
staining (ICS), PBMCs were incubated with LoMo megapool or 
PUR extract for 24 h. After 20 h, BFA [5 μg/ml (BD Bioscience, 
San Diego, CA, USA)] was added for an additional 4 h. Cells 
were then washed, stained for extracellular markers for 30 min, 
washed again, fixed with 4% paraformaldehyde, permeabilized 
with 0.5% saponin (Sigma), and stained for intracellular 
IL-4-BV421, IL-5-PE, IL-17-FITC, and IFN-γ-PerCPCy5.5 
FigUre 1 | Length distribution of unmodified and modified identified peptides. Liquid chromatography–mass spectrometry of <3 kDa mouse urine fraction detected 
over 1,300 distinct peptiforms. Graph depicts the summary of the amino acid length distribution of non-modified (746) and modified peptides (615) at a high 
confidence level.
4
da Silva Antunes et al. Mouse Urine-Associated T Cell Allergic Responses
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 886
(Table S2 in Supplementary Material). PMA and ionomycin 
(1 and 0.1 µg/ml) were used as positive control. Samples were 
acquired on a BD LSRII Flow Cytometer and analyzed using 
FlowJo X Software.
resUlTs
identification of Oligopeptides From 
Mouse Urine Filtrate
In the context of an independent study to characterize conven-
tional murine allergens, we prepared and purified mouse urine 
extracts. The purification process entailed repeated ultracen-
trifugation steps through a 3  kDa Centricon membrane. The 
total protein content of the ultrafiltrate (endproduct after six 
washes and filtration steps) derived from 60 ml of urine was 
162.8 mg by BCA assay. In contrast, the protein content of the 
seven filtrates flow-through samples yielded a total of 347 mg. 
These data suggest that a large amount of protein/peptide/amino 
acid content in the mouse urine comes from low molecular 
weight material, consistent with previous reports (8, 25, 32). 
Comparative gel analysis of whole urine to the purified/desalted 
protein sample did not reveal significant differences both in 
terms of identity and quantity of the bands suggesting that 
the lower content of BCA-reactive material in the ultrafiltrate 
was not due to protein loss during the ultrafiltration process 
(data not shown).
We therefore hypothesized that the BCA-detected material 
of less than 3  kDa in size could be accounted for, at least in 
part, by oligopeptides. Peptides greater than 9 residues in size 
are recognized by T  cells but will be missed by any analyses 
based on IgE binding. To address this point, we performed 2D 
LCMS to identify specific peptide sequences, after de-salting the 
sample by gel chromatography. Spectra were searched against 
the M. musculus database using a set of variable common post-
translational modifications. This analysis detected over 1,300 
distinct peptiforms with 746 non-modified and 615 modified 
peptides at a high confidence level (Table S3 in Supplementary 
Material). Furthermore, most of the peptiforms (1,129) were >9 
amino acids in length, with a median of 15 and 11 amino acids 
for modified and unmodified peptides, respectively. A summary 
of the length distribution of all identified peptides is shown in 
Figure 1.
In all, there were 265 unique non-modified peptides of 13 or 
more residues in size. Many of these peptides were largely overlap-
ping with other peptides derived from the same source protein. 
For example, four peptides of different lengths from Mep1a were 
observed (YSGDNDAILEWPVENR, YSGDNDAILEW PVEN 
RQ, YSGDNDAILEWPVENRQA, and YSGDNDAILEWPVE 
NRQAI). These four peptides were accordingly grouped in a sin-
gle “cluster” represented by the YSGDNDAILEWPVENRQAI 
species. After this clustering reduction was completed, there 
were 164 clusters of one or more peptides representing 164 dif-
ferent locations across 54 source proteins. A total of 21 proteins 
FigUre 2 | LoMo peptides induce antigen-specific responses for T cells derived from mouse allergic donors. Cytokine production was measured by ELISPOT 
following in vitro restimulation with LoMo peptides or urine/epithelial extract. Donor response frequency (a) and breadth of responses (B) were compared between 
antigenic stimulation by exact fisher test. (c) Magnitude of responses expressed by spot-forming cells (SFC). Median is shown. Each dot represents combined  
IL-5 and IFNγ responses of one donor. Statistical analysis was performed by two-tailed Mann–Whitney test.
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contributed 10 or more peptiforms, suggesting that the peptides 
were derived from a relatively narrow set of proteins (Table S4 
in Supplementary Material). By far, the most common post-
translational modification observed was hydroxyproline (42%), 
and most of these peptides originated from collagen (Figure S1 
in Supplementary Material). Indeed, we detected over 300 colla-
gen derived peptides associated with mono- or di-hydroxylated 
prolines, also consistent with previous reports reporting that 
hydroxylated collagen peptides are relatively abundant in urine 
(33). Accordingly, we next synthesized the longest peptide 
from each of the 164 clusters and 61 hydroxyproline peptides. 
In all, this corresponds to 225 peptides derived from the low 
molecular weight fraction of mouse urine, hereafter as “LoMo” 
peptides.
Urine low Molecular Weight Fraction 
(loMo) Peptides are recognized by  
T cells From Mouse allergic Donors
Next, to determine whether LoMo peptides were recognized 
by human T  cells, we assessed their antigenicity in PBMC 
from a cohort of 19 mouse-sensitized donors (Table S1 in 
Supplementary Material). A total of 225 peptides from 68 pro-
teins were screened after PBMC expansion with pools of LoMo 
peptides.
Strong reactivity was detected and directed against a total of 
116 peptides (Table S5 in Supplementary Material). The overall 
response frequency was 94.7% (18/19 donors), and the median 
total response magnitude (sum of IFNγ and IL-5) was 5,210 
SFC/donor (Figure  2). The results were initially depicted as 
sum of IFNγ and IL-5 to simplify the flow of the manuscript. 
The relative contribution of IFNγ and IL-5 to total reactivity is 
detailed in Figure 3D below which addresses polarization of the 
responses.
As a control, the same 225 peptides were screened after 
14-day in  vitro expansion with either mouse high molecular 
weight purified urine (PUR) or mouse epithelial (EPTH) 
extract. In the experiments in Figure 2, PBMCs were expanded 
for 14  days with LoMo peptides before testing for reactivity 
against the LoMo peptides. Expansion with epithelial/urine 
extract before testing against the LoMo peptides was also used 
as a control; since the LoMo peptides were not contained in 
the PUR/EPTH extract we expected that LoMo reactive T cells 
would not be effectively expanded. Thus, we expected lower 
reactivity, potentially indicative of some degree of cross-
reactivity between high molecular weight products and LoMo 
peptides. Whenever possible, the same donors also tested for 
reactivity to the LoMo peptides were utilized for these con-
trol experiments. In some cases, however, limitations in cell 
numbers did not allow for testing the same donors, in which 
cases additional donors with same clinical characteristics were 
tested, to provide a comparable number of donors tested with 
LoMo and the high molecular weight extracts (see Table S6 in 
Supplementary Material for a complete listing of the peptides 
FigUre 3 | LoMo immunodominance, protein source, and response polarization. (a) Epitopes ranked on the basis of magnitude of response. Dotted lines indicate 
the top 10 (42.6% of total response) and top 46 (90% of total response) epitopes. (B) Breadth of response indicated by proportion of donors who respond to the 
specified number of epitopes. (c) Total spot-forming cells (SFC) detected against peptides from urine/kidney or non-urine protein sources. (D) Pattern of cytokine 
production expressed as proportion of IFNγ or IL-5 for all the reactive peptides.
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for which responses were detected following expansion with 
high molecular weight extracts).
Following PUR/EPTH expansion and assessment of reacti-
vity against LoMo peptides, the overall response frequency was 
10/22, which is significantly lower (p = 0.0008 by the exact Fisher 
test) compared with LoMo expansion (Figure 2A). In addition, 
breadth of recognition (no. of epitopes) was also significantly 
reduced (21 peptides after PUR/EPTH expansion vs. 116 pep-
tides after LoMo expansion) (p  <  0.0001 by the exact Fisher 
test) (Figure 2B), and the median total magnitude of responses 
was also significantly lower compared with LoMo expansion 
(p = 0.0001 by the Mann–Whitney test) (Figure 2C).
These results demonstrate that LoMo peptides are potent 
inducers of T cell reactivity in mouse allergic donors and that the 
observed responses are largely not due to epitope cross-reaction 
with high molecular weight extract products, but instead to origi-
nal epitopes identified within the low molecular weight fraction 
of mouse urine.
characterization of loMo responses  
in Terms of immunodominance, Protein 
source, and response Polarization
We next scrutinized the specificity of LoMo responses in more 
detail. The top 46 epitopes accounted for 90% and the top 
10 epitopes for 42.6% of the total magnitude of the detected 
responses (Figure  3A). As shown in Figure  3B, 94.7% of 
donors recognized at least one epitope, and 73.7% of the donors 
responded to ≥10 epitopes.
LoMo responses, on a per donor basis, tended to be distrib-
uted among a relatively high number of recognized peptides 
(median of 13 epitopes/donor). Indeed, a total of 50 epitopes 
were recognized in at least 3 out of the 19 donors tested, cor-
responding to a frequency of recognition of 15.8% (see Table 
S5 in Supplementary Material). Moreover, 15 epitopes were 
recognized in 31.6% of the donors (6/19 positives). Interestingly, 
within the top 46 peptides accounting for 90% of the total 
TaBle 2 | Protein sources of non-urine reactive peptides.
non-urine proteins response frequency (%) Total spot-forming 
cells
% of Total 
response
Egf protein 52.6 30,330 15.9
Collagen and collagen precursors 26.3 17,485 9.2
Beta-globin 26.3 15,478 8.1
Meprin A subunit alpha (EC 3.4.24.18) (endopeptidase-2) (MEP-1) 36.8 9,063 4.8
Putative uncharacterized protein 36.8 6,822 3.6
Leucine-rich HEV glycoprotein (leucine-rich alpha-2-glycoprotein) (protein Lrg1) 52.6 6,315 3.3
Cfd protein [complement factor D (Adipsin), isoform CRA_a] 10.5 4,167 2.2
Lacrein (protein Gm1553) 52.6 3,722 2.0
Pancreatic alpha-amylase (PA) (EC 3.2.1.1) (1,4-alpha-d-glucan glucanohydrolase) 36.8 2,708 1.4
Fibrinogen alpha chain (cleaved into: fibrinopeptide A; fibrinogen alpha chain) 15.8 2,653 1.4
Fibronectin 10.5 2,547 1.3
Protein Bpifb9b 21.1 2,493 1.3
Alpha-1-antitrypsin 1-3 (alpha-1 protease inhibitor 3) (Serpin A1c) 26.3 2,370 1.2
Beta-geo 15.8 1,723 0.9
SH3 domain-binding glutamic acid-rich-like protein 3 21.1 1,597 0.8
Insulin-2 (fragment) 15.8 923 0.5
Tripeptidyl peptidase I, isoform CRA_a 15.8 913 0.5
Alpha-2-HS-glycoprotein (countertrypin) (Fetuin-A) 26.3 810 0.4
Igk protein 31.6 775 0.4
Cadherin 1, isoform CRA_a (Cdh1 protein) 26.3 632 0.3
Hemoglobin 10.5 600 0.3
Seminal vesicle secretory protein 4 (seminal vesicle protein 2) (SVS IV) 10.5 595 0.3
Vasodilator-stimulated phosphoprotein (VASP) 10.5 475 0.2
Cathelicidin (fragment) 10.5 370 0.2
Deoxyribonuclease-1 (EC 3.1.21.1) (Deoxyribonuclease I) (DNase I) 5.3 240 0.1
Serine protease inhibitor A3K (Serpin A3K) (contrapsin) (SPI-2) 5.3 210 0.1
Asialoglycoprotein receptor 1 (asialoglycoprotein receptor 1, isoform CRA_b) 10.5 173 0.1
ATP-binding cassette sub-family A member 13 10.5 150 0.1
Lysosomal thioesterase PPT2 (fragment) 15.8 120 0.1
Beta-2-microglobulin 10.5 103 0.1
Espin 10.5 97 0.1
Apolipoprotein E 5.3 83 0.04
Carbonic anhydrase 1 (EC 4.2.1.1) (carbonate dehydratase I) (carbonic anhydrase I) (CA-I) 5.3 57 0.03
Apolipoprotein A-II (Apo-AII) (ApoA-II) (apolipoprotein A2) 5.3 53 0.03
Alpha-1-acid glycoprotein 2 (AGP 2) (orosomucoid-2) (OMD 2) 5.3 50 0.03
Acetylcholinesterase collagenic tail peptide 5.3 27 0.01
TaBle 1 | Protein sources of urine or kidney reactive peptides.
Urine or kidney related proteins response frequency (%) Total spot-forming cells % of Total response
Major urinary protein 13 84.2 42,878 22.5
MCG15829, isoform CRAa (major urinary protein 25) (major urinary protein 3) 42.1 10,825 5.7
Kidney androgen-regulated protein (ARP) (KAP) 52.6 9,437 5.0
Major urinary protein 14 (major urinary protein 17) 31.6 5,183 2.7
Major urinary protein 20 (Darcin) (major urinary protein 24) 15.8 2,985 1.6
Uromodulin (Tamm–Horsfall urinary glycoprotein) (THP) 21.1 2,317 1.2
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response, 5 peptides contained hydroxyproline residues, and 1 
particular hydroxyproline peptide elicited the highest magni-
tude of response (7% of total response).
In terms of protein source, Table S5 in Supplementary 
Material also lists whether the proteins from which the peptides 
are derived are urinary/kidney proteins or not. Strikingly, the 
majority (94/116) of the immunogenic peptides were derived 
from non-urine related sources representative of 36 different 
proteins. These peptides accounted for a higher magnitude 
of responses (61.4%) than urine and kidney related proteins 
(Figure 3C). Major urinary proteins, KAP, leucine-glycoprotein, 
uromodulin, collagen, Meprin A, and Egf have already been 
reported previously in urinepeptidome studies (25, 34, 35). 
However, for other proteins, like Lacrein or Beta-globin, this is 
the first time that peptides from these protein sources have been 
reported to be present in urine, as well as being targets of T cell 
reactivity in mouse allergic donors. The data shown in Tables 1 
and 2 emphasizes that the high amount of non-urine sources 
contributes to T-cell responses, as also mentioned earlier in 
Figure 3C. SFC of each individual peptide across all donors was 
summed as groups of peptides from same protein source. The 
% total response for a given protein is the relative contribution 
of that protein in the overall responses for the entire sources of 
proteins.
FigUre 4 | IgE reactivity against PUR extract, LoMo peptides, and 
epidermal growth factor (EGF). IgE from plasma of mouse allergic donors 
was measured by ELISA against coated LoMo peptides, urine high molecular 
extract (PUR) fraction, or rEGF. Concentration values for each condition were 
extrapolated from a calibration curve generated with recombinant IgE 
titrations read in the same plate. Values represent the average of duplicates, 
and each dot represents one donor. Detection limit (7.8 ng/ml) represents the 
sensitivity of the assay.
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Allergic T cell response is known to be predominantly associ-
ated with responses of the Th2 subset (36, 37). Here we sought 
to further characterize the polarization of LoMo-specific T cell 
responses based on IFNγ/IL-5 production per epitope tested. As 
expected, T  cell reactivity in response to stimulation with the 
individual peptides was dominated by IL-5 production, which 
accounted for 63.1% of the total responses (Figure 3D). The sum 
of IFNγ and IL-5 responses for all the reactive peptides across all 
donors defines the value accounting for 100% of responses. The 
relative contribution of either IFNγ or IL-5 production is repre-
sented in the pie chart as the fraction of responses accounted by 
each cytokine. Double positive cells (producing both cytokines) 
were generally not observed. The ex vivo responses results pre-
sented below in Figure 6C also support this notion.
ige reactivity against PUr extract,  
loMo Peptides, and egF restriction  
of Dominant epitopes
Further experiments addressed the IgE reactivity of LoMo 
peptides, tested as a pool, and reactivity against EGF, the most 
reactive non-urine protein from which the LoMo was derived. 
The rationale for these experiments was first to demonstrate 
that, as expected LoMo peptides were, because of their small 
size, largely non-IgE reactive. Furthermore, testing for recogni-
tion of a representative full-length protein was of interest in 
terms of the characterization of these novel responses, to exam-
ine whether also antibodies against the corresponding novel 
proteins exist. The results show that as expected, good reactiv-
ity was noted against the positive control, the high molecular 
extract (PUR) fraction of the urine (Figure 4), but the LoMo 
peptides were largely non-reactive. Interestingly, reactivity was 
also detected against EGF, suggesting that the LoMo peptides 
might actually also be linked to the identification of novel IgE 
reactive proteins.
inferred hla restriction of Dominant 
epitopes
HLA typing was performed as described in the Methods (Table 
S7 in Supplementary Material). To analyze the potential rela-
tion between the HLA class II genotype of subjects and their 
response to LoMo epitopes, we used the RATE program (30) 
to calculate the relative frequency and significance of asso-
ciation between all the epitopes/regions and HLA alleles (or 
combinations thereof) expressed in responding donors. This 
analysis allowed inferring potential restrictions for the four of 
the main epitopes. It should be emphasized that these inferred 
alleles are meant to restrict the potential choices for the most 
likely restricting elements, and that further experimentation is 
required to conclusively assign restriction.
Table S7 in Supplementary Material lists for each of the 
peptides the inferred restrictions and details the number and 
combinations of donors that responded (R+) or did not respond 
(R−) to a given peptide, and the number of donors expressing 
(A+) or not expressing (A−) a given HLA(s). Accordingly, for 
example, the SSLKHPSNIAVDPIERL epitope, 100% (4/4) of the 
responders express the HLA DQA1*03:01, allele while none of 
the non-responders expressed the same HLAs (p = 0.008).
Detection of human loMo-specific  
cD4+ T cells Ex Vivo allows to Further 
characterize specificity and Phenotype  
of responses
To further establish the biological relevance of these observa-
tions and to exclude the possibility that the responses detected 
were an artifact induced by in  vitro expansion, we tested a 
megapool consisting of all 225 LoMo peptides for its capacity 
to induce ex vivo T cell activation. For this purpose, cells were 
stimulated for 24 h with LoMo megapool followed by enrich-
ment for the activation marker 4-1BB. Subsequently, enriched 
cells were stained with an antibody cocktail against activation 
and memory-specific surface markers, and T  cell activation 
was determined by flow cytometry, assessing dual expression of 
4-1BB and OX40 (Figure 5A).
Here, T  cell responses were measured directly ex vivo, and 
therefore the data allow to compare the relative magnitude 
and frequency of responses of T  cells specific for either LoMo 
peptides or the high molecular extract (PUR) fraction of the 
urine. LoMo responses were detected in 11/18 donors. To further 
investigate the contribution of LoMo-specific T cell responses to 
mouse allergy, we also tested ex vivo T cell activation to the high 
molecular weight (>3 kDa) mouse urine extract (PUR). The PUR 
extract elicited the highest reactivity in 15/18 donors (83%). By 
comparison, responses against the LoMo pool were seen in 61% 
of the donors (Figure  5). In terms of magnitude, PUR extract 
reactivity was associated with a higher reactivity of responses, 
with a median SI of 4.7 (Figure 5C). The responses against the 
LoMo pool had a median SI of 2.8 (Figure 5C). In conclusion, 
LoMo reactivity was, albeit lower than PUR reactivity, fairly 
comparable in frequency and magnitude.
The ex vivo assay modality was further used to address the 
specificity of responses, namely whether LoMo responses were 
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specifically associated with donors sensitized to mouse allergens. 
Accordingly, we also tested a group of subjects non-allergic to 
mouse allergens. As expected few responses and little reactivity 
were detected (Figure 5D), with a response rate of 2/10 donors 
and a median SI of 1.02. As shown in Figure 5E, the number of 
LoMo reactive CD4+ T cells is significantly lower than observed 
in the mouse allergic counterparts (p = 0.0271).
Finally, LoMo-specific CD4+ T  cell reactivity was associ-
ated with a memory phenotype involving both central (TCM, 
CD45RA−CCR7+) and effector (TEM, CD45RA−CCR7−) memory 
subsets (Figure 6A). The relative frequency of TCM or TEM was 
not significantly different between LoMo and PUR stimulation 
(Figure 6B). As expected, and paralleling in vitro restimulation 
results, IL-5 along with IL-4 was the cytokine most abundantly 
secreted after LoMo stimulation, as detected by intracellular stain-
ing (Figure 6C). No significant differences were detected in the 
polarization of responses between LoMo and PUR conditions for 
a limited number of donors analyzed (Figure 6D). The sum of the 
percentage of positive responses for IFNγ+IL-5+IL4+IL-17 for each 
donor was used to define the 100% of responses value. The relative 
contribution of each cytokine is represented in the pie chart as 
the fraction of responses accounted by each cytokine. Admittedly, 
double-positive responses cannot be extrapolated from this 
representation. In general, as shown for a representative donor, 
cells producing both IL-4 and IL-5 were common (Figure  6C, 
left), while no overlap existed between cells producing IFNγ and 
IL-17 (Figure 6C, middle), or IFNγ and IL-5 (Figure 6C, right). 
These results indicate that the LoMo-specific CD4+ T cell reactiv-
ity is associated with Th2 memory cells.
DiscUssiOn
Here, we report the first description of T cell recognition, in mouse 
allergic donors, of peptides found naturally in the low molecular 
weight fraction of mouse urine. This study was conceived based 
on the large amount of proteinaceous material found within the 
filtrate of purified mouse extract.
FigUre 5 | Ex vivo detection of human LoMo-specific CD4+ T cells. (a) Representative flow cytometry plots of 4-1BB+OX40+ upregulation by CD4+ T cells  
after stimulation with DMSO, LoMo, or PUR extract for 24 h. (B) Graph shows total number of stimulated 4-1BB+OX40+CD4+ T cells per 1 × 106 PBMCs after 
AIM/4-1BB enrichment assays. Median ± interquartile range is represented for each stimulus. Statistical analysis was performed by Friedman’s non-parametric 
repeated measures comparisons. (c) Median of total number of activated T cells represented as fold over background (DMSO). Positive reactivity was defined  
as stimuli index >2-fold. Each dot represents one donor. (D) Total number of allergic vs. non-allergic activated CD4+ T cells after AIM/4-1BB enrichment assays. 
Median ± interquartile range is represented for each stimuli (e) Median of total number of LoMo-specific T cells subtracted over background (DMSO). Each dot 
represents one donor. Statistical analysis was performed by two-tailed Mann–Whitney test.
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FigUre 6 | Phenotype and polarization of human LoMo-specific CD4+ T cells ex vivo. (a) Representative flow cytometry plots of 4-1BB+OX40+CD4+ T cells gated 
on CD45RA and CCR7 expression after 24 h of stimulation. (B) Graph shows frequency of central memory (CD45RA−CCR7+), effector memory (CD45RA−CCR7−), 
naïve (CD45RA+CCR7+), and TEMRA (CD45RA+CCR7−) cells. Median ± interquartile range is represented for each population. (c) Representative flow cytometry 
plots of 4-1BB+OX40+CD4+ T cells LoMo-specific cytokine production after AIM and ICS assays combined. (D) Patterns of cytokine production in LoMo or PUR 
antigen-specific T cells expressed as frequency of each individual cytokine (n = 4) donors.
The recognition of small molecular weight material in urine 
by T cells from allergic donors is not completely unprecedented, 
as low molecular weight haptens and drug molecules have long 
been recognized as potent allergens, and T  cell based models 
of allergic reactions commonly utilize these types of reagents 
(38–40). Future experiments addressing whether the associated 
T cells express skin or lung homing markers might help to deter-
mine the route of exposure of these components to the immune 
system.
Consistent with previous reports (9, 25), the urine pepti-
dome detected by mass spectrometry was highly diverse, with 
over 1,300 distinct peptiforms in the low molecular weight 
fraction. Strikingly, the universe of peptides recognized by 
T cells was also remarkably heterogeneous, with about half of 
the 225 peptides tested being recognized by at least one of the 
allergic donors tested. This finding further underlines how the 
low molecular weight fraction represents a previously under-
appreciated but rich source of antigenic peptides.
Posttranslationally modified peptides were abundant in the 
low molecular weight fraction. The most common posttransla-
tional modification was hydroxyproline, whose predominant 
source was collagen. Indeed, this was already observed previ-
ously and represents a major route for collagen breakdown 
and excretion (33). Of relevance, hydroxyproline-containing 
peptides are relatively resistant to exoprotease degradation (41), 
which is a factor that could contribute to their immunogenicity. 
Immunogenic hydroxyproline peptides have previously been 
described in models of collagen induced arthritis (42). Here, the 
highest response magnitude was elicited by a hydroxyproline 
peptide, which was recognized in 4 out of 19 donors. Peptides 
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